167 related articles for article (PubMed ID: 8881370)
1. The role of interferon in the therapy of malignant lymphoma.
McLaughlin P
Biomed Pharmacother; 1996; 50(3-4):140-8. PubMed ID: 8881370
[TBL] [Abstract][Full Text] [Related]
2. Can we cure indolent lymphomas?
Cabanillas F
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2655-9. PubMed ID: 10068269
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. [Recent progress in the treatment of malignant lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1213-35. PubMed ID: 11579632
[TBL] [Abstract][Full Text] [Related]
5. [Interferon-alpha therapy in non-Hodgkin's lymphoma].
Fridrik MA
Wien Med Wochenschr; 1993; 143(16-17):429-34. PubMed ID: 8273367
[TBL] [Abstract][Full Text] [Related]
6. Current status of interferons in the treatment of cancer.
Hansen RM; Borden EC
Oncology (Williston Park); 1992 Nov; 6(11):19-24; discussion 26, 29. PubMed ID: 1280153
[TBL] [Abstract][Full Text] [Related]
7. Occurrence of Hodgkin's disease and cutaneous B-cell lymphoma in the same patient: a report of two cases.
Servitje O; Martí RM; Estrach T; Palou J; Gallardo F; Limón A; Romagosa V
Eur J Dermatol; 2000; 10(1):43-6. PubMed ID: 10694298
[TBL] [Abstract][Full Text] [Related]
8. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
9. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
[TBL] [Abstract][Full Text] [Related]
10. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens.
Ardeshna KM; Kakouros N; Qian W; Powell MG; Saini N; D'Sa S; Mackinnon S; Hoskin PJ; Goldstone AH; Linch DC
Br J Haematol; 2005 Aug; 130(3):363-72. PubMed ID: 16042685
[TBL] [Abstract][Full Text] [Related]
11. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
[TBL] [Abstract][Full Text] [Related]
13. [Medicinal therapy of malignant lymphomas].
Aul C; Schroeder M; Giagounidis A
Radiologe; 2002 Dec; 42(12):943-53. PubMed ID: 12486548
[TBL] [Abstract][Full Text] [Related]
14. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
15. Interferon in the treatment of cutaneous T-cell lymphoma.
Olsen EA; Bunn PA
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1089-107. PubMed ID: 8522486
[TBL] [Abstract][Full Text] [Related]
16. A single-center study of treatment outcomes and survival in patients with primary gastric lymphomas between 1990 and 2003.
Jezersek Novaković B; Vovk M; Juznic Setina T
Ann Hematol; 2006 Dec; 85(12):849-56. PubMed ID: 16944146
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
18. [Interferon (IFN) in multiple myeloma and non-Hodgkin's lymphoma].
Gola A
Acta Haematol Pol; 1994; 25(2 Suppl 1):136-41. PubMed ID: 7520658
[TBL] [Abstract][Full Text] [Related]
19. T-cell lymphoma presenting as a rapidly enlarging tumor on the lower eyelid.
Onesti MG; Mazzocchi M; De Leo A; Scuderi N
Acta Chir Plast; 2005; 47(3):65-6. PubMed ID: 16173513
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in indolent and aggressive lymphomas and its influence on disease outcome.
Zodelava M; Betaneli M; Tsartsidze E; Kharabadze M
Georgian Med News; 2009 Feb; (167):32-6. PubMed ID: 19276466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]